Top

Open Access 29-04-2024 | Insulins | Review

Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes

Authors: Roberto Trevisan, Matteo Conti, Stefano Ciardullo

Abstract

Despite the availability of new classes of glucose-lowering drugs that improve glycaemic levels and minimise long-term complications, at least 20–25% of people with type 2 diabetes require insulin therapy. Moreover, a substantial proportion of these individuals do not achieve adequate metabolic control following insulin initiation. This is due to several factors: therapeutic inertia, fear of hypoglycaemia and/or weight gain, poor communication, complexity of insulin titration, and the number of injections needed, with the associated reduced adherence to insulin therapy. Once-weekly insulins provide a unique opportunity to simplify basal insulin therapy and to allow good glycaemic control with a low risk of hypoglycaemia. Several approaches to developing a stable and effective once-weekly insulin have been proposed, but, to date, insulin icodec and basal insulin Fc (insulin efsitora alfa) are the only two formulations for which clinical studies have been reported. The results of Phase I and II studies emphasise both efficacy (in term of glucose levels) and potential risks and adverse events. Phase III studies involving insulin icodec are reassuring regarding the risk of hypoglycaemia compared with daily basal insulin analogues. Despite some concerns raised in ongoing clinical trials, the available data suggest that weekly insulins may also be an option for individuals with type 1 diabetes, especially when adherence is suboptimal. For the first time there is an opportunity to make an important breakthrough in basal insulin therapy, particularly in people with type 2 diabetes, and to improve not only the quality of life of people with diabetes, but also the practice of diabetologists.

Graphical Abstract

Available only for authorised users

Sun H, Saeedi P, Karuranga S et al (2022) IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119. https://doi.org/10.1016/j.diabres.2021.109119CrossRefPubMed

Diabetes Control Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329(14):977–986. https://doi.org/10.1056/NEJM199309303291401CrossRef

Turner RC, Holman RR, Cull CA et al (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837–853. https://doi.org/10.1016/S0140-6736(98)07019-6CrossRef

Sattar N, Lee MM, Kristensen SL et al (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9(10):653–662. https://doi.org/10.1016/S2213-8587(21)00203-5CrossRefPubMed

Bhattarai M, Salih M, Regmi M et al (2022) Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in patients with type 2 diabetes and other risk factors for cardiovascular disease: a meta-analysis. JAMA Network Open 5(1):e2142078. https://doi.org/10.1001/jamanetworkopen.2021.42078CrossRefPubMedPubMedCentral

ElSayed NA, Aleppo G, Aroda VR et al (2023) 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2023. Diabetes Care 46(Supplement_1):S140–S157. https://doi.org/10.2337/dc23-S009CrossRefPubMed

UK Prospective Diabetes Study Group (1995) UK Prospective Diabetes Study 16: overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 44(11):1249–1258. https://doi.org/10.2337/diab.44.11.1249CrossRef

Fang M, Wang D, Coresh J, Selvin E (2021) Trends in diabetes treatment and control in US adults, 1999–2018. N Engl J Med 384(23):2219–2228. https://doi.org/10.1056/NEJMsa2032271CrossRefPubMedPubMedCentral

Home PD, Mehta R (2021) Insulin therapy development beyond 100 years. The Lancet Diabetes Endocrinol 9(10):695–707. https://doi.org/10.1016/S2213-8587(21)00182-0CrossRefPubMed

10.

Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T (2008) Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 371(9618):1073–1084. https://doi.org/10.1016/S0140-6736(08)60485-7CrossRefPubMed

11.

Wysham C, Bhargava A, Chaykin L et al (2017) Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA 318(1):45–56. https://doi.org/10.1001/jama.2017.7117CrossRefPubMedPubMedCentral

12.

Ritzel R, Roussel R, Bolli G et al (2015) Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab 17(9):859–867. https://doi.org/10.1111/dom.12485CrossRefPubMedPubMedCentral

13.

Sullivan SD, Nicholls CJ, Gupta RA et al (2019) Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: the DELIVER naive D real-world study. Diabetes Obes Metab 21(9):2123–2132. https://doi.org/10.1111/dom.13793CrossRefPubMedPubMedCentral

14.

Peyrot M, Rubin RR, Lauritzen T et al (2005) Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 28(11):2673–2679. https://doi.org/10.2337/diacare.28.11.2673CrossRefPubMed

15.

Polonsky W, Fisher L, Hessler D, Bruhn D, Best J (2011) Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab 13(2):144–149. https://doi.org/10.1111/j.1463-1326.2010.01327.xCrossRefPubMed

16.

Rosenstock J, Del Prato S (2022) Basal weekly insulins: the way of the future! Metabolism 126:154924. https://doi.org/10.1016/j.metabol.2021.154924CrossRefPubMed

17.

Kjeldsen TB, Hubalek F, Hjørringgaard CU et al (2021) Molecular engineering of insulin icodec, the first acylated insulin analog for once-weekly administration in humans. J Med Chem 64(13):8942–8950. https://doi.org/10.1021/acs.jmedchem.1c00257CrossRefPubMed

18.

Nishimura E, Pridal L, Glendorf T et al (2021) Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing. BMJ Open Diabetes Res Care 9(1):e002301. https://doi.org/10.1136/bmjdrc-2021-002301CrossRefPubMedPubMedCentral

19.

Plum-Mörschel L, Andersen LR, Hansen S et al (2023) Pharmacokinetic and pharmacodynamic characteristics of insulin icodec after subcutaneous administration in the thigh, abdomen or upper arm in individuals with type 2 diabetes mellitus. Clin Drug Investig 43(2):119–127. https://doi.org/10.1007/s40261-022-01243-6CrossRefPubMedPubMedCentral

20.

Rath T, Baker K, Dumont JA et al (2015) Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol 35(2):235–254. https://doi.org/10.3109/07388551.2013.834293CrossRefPubMed

21.

Moyers JS, Hansen RJ, Day JW et al (2022) Preclinical characterization of LY3209590, a novel weekly basal insulin Fc-fusion protein. J Pharmacol Exp Ther 382(3):346–355. https://doi.org/10.1124/jpet.122.001105CrossRefPubMed

22.

Heise T, Chien J, Beals JM et al (2022) Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (BIF, insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes mellitus. Diabetes Obes Metab 25(4):1080–1090. https://doi.org/10.1111/dom.14956CrossRef

23.

Rosenstock J, Bajaj HS, Janež A et al (2020) Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med 383(22):2107–2116. https://doi.org/10.1056/NEJMoa2022474CrossRefPubMed

24.

Lingvay I, Buse JB, Franek E et al (2021) A randomized, open-label comparison of once-weekly insulin icodec titration strategies versus once-daily insulin glargine U100. Diabetes Care 44(7):1595–1603. https://doi.org/10.2337/dc20-2878CrossRefPubMedPubMedCentral

25.

Bajaj HS, Bergenstal RM, Christoffersen A et al (2021) Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care 44(7):1586–1594. https://doi.org/10.2337/dc20-2877CrossRefPubMedPubMedCentral

26.

Frias J, Chien J, Zhang Q et al (2023) Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study. Lancet Diabetes Endocrinol 11(3):158–168. https://doi.org/10.1016/S2213-8587(22)00388-6CrossRefPubMed

27.

Bue-Valleskey JM, Kazda CM, Ma C et al (2023) Once-weekly basal insulin Fc demonstrated similar glycemic control to once-daily insulin degludec in insulin-naive patients with type 2 diabetes: a phase 2 randomized control trial. Diabetes Care 46(5):1060–1067. https://doi.org/10.2337/dc22-2396CrossRefPubMedPubMedCentral

28.

Kazda CM, Bue-Valleskey JM, Chien J et al (2023) Novel once-weekly basal insulin Fc achieved similar glycemic control with a safety profile comparable to insulin degludec in patients with type 1 diabetes. Diabetes Care 46(5):1052–1059. https://doi.org/10.2337/dc22-2395CrossRefPubMedPubMedCentral

29.

Lingvay I, Asong M, Desouza C et al (2023) Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive type 2 diabetes: the ONWARDS 3 randomized clinical trial. JAMA 330(3):228–237. https://doi.org/10.1001/jama.2023.11313CrossRefPubMedPubMedCentral

30.

Bajaj HS, Aberle J, Davies M et al (2023) Once-weekly insulin icodec with dosing guide app versus once-daily basal insulin analogues in insulin-naive type 2 diabetes (ONWARDS 5) a randomized trial. Ann Intern Med 176(11):1476–1485. https://doi.org/10.7326/M23-1288CrossRefPubMed

31.

Rosenstock J, Bain SC, Gowda A et al (2023) Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med 389(4):297–308. https://doi.org/10.1056/NEJMoa2303208CrossRefPubMed

32.

Philis-Tsimikas A, Asong M, Franek E et al (2023) Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol 11(6):414–425. https://doi.org/10.1016/S2213-8587(23)00093-1CrossRefPubMed

33.

Mathieu C, Ásbjörnsdóttir B, Bajaj HS et al (2023) Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet 401(10392):1929–1940. https://doi.org/10.1016/S0140-6736(23)00520-2CrossRefPubMed

34.

Russell-Jones D, Babazono T, Cailleteau R et al (2023) Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial. Lancet 402(10413):1636–1647. https://doi.org/10.1016/S0140-6736(23)02179-7CrossRefPubMed

35.

Philis-Tsimikas A, Bajaj HS, Begtrup K et al (2023) Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once-weekly insulin icodec in diabetes. Diabetes Obes Metab 25(2):331–341. https://doi.org/10.1111/dom.14871CrossRefPubMed

36.

Singh AK, Singh A, Singh R, Misra A (2022) Once-weekly basal insulin icodec: looking ONWARDS from pharmacology to clinical trials. Diabetes Metab Syndr Clin Res Rev 16(9):102615. https://doi.org/10.1016/j.dsx.2022.102615CrossRef

37.

Soetedjo NNM, Permana H, Hariyanto TI et al (2023) Once-weekly insulin icodec as novel treatment for type 2 diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials. Diabetes Res Clin Pract 205:110984. https://doi.org/10.1016/j.diabres.2023.110984CrossRef

38.

ClinicalTrials.gov [Internet], National Library of Medicine, Bethesda, MD, USA. 29 Feb 2000. NCT05662332. A study of LY3209590 compared to glargine in adult participants with type 2 diabetes who are starting basal insulin for the first time (QWINT-1). 22 Dec 2022. Available from: https://ClinicalTrials.gov/show/NCT05662332. Accessed 12 Feb 2024

39.

ClinicalTrials.gov [Internet], National Library of Medicine, Bethesda, MD, USA. NCT05463744. A study of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy (QWINT-5). 19 July 2022. Available from: https://ClinicalTrials.gov/show/NCT05463744. Accessed 12 Feb 2024

40.

ClinicalTrials.gov [Internet], National Library of Medicine, Bethesda, MD, USA. NCT05462756. A study of insulin efsitora alfa (LY3209590) as a weekly basal insulin compared to insulin glargine in adult participants with type 2 diabetes on multiple daily injections (QWINT-4). 18 July 2022. Available from: https://ClinicalTrials.gov/show/NCT05462756. Accessed 12 Feb 2024

41.

ClinicalTrials.gov [Internet], National Library of Medicine, Bethesda, MD, USA. NCT05362058. A study of insulin efsitoria alfa (LY3209590) compared to degludec in adults with type 2 diabetes who are starting basal insulin for the first time (QWINT-2). 5 May 2022. Available from: https://ClinicalTrials.gov/show/NCT05362058. Accessed 12 Feb 2024

42.

ClinicalTrials.gov [Internet], National Library of Medicine, Bethesda, MD, USA. NCT05275400. A study of insulin efsitoria alfa (LY3209590) compared with insulin degludec in participants with type 2 diabetes currently treated with basal insulin. 11 March 2022. Available from: https://ClinicalTrials.gov/show/NCT05275400. Accessed 12 Feb 2024

43.

ClinicalTrials.gov [Internet], National Library of Medicine, Bethesda, MD, USA. NCT05352815. A research study to see how well the new weekly medicine icosema, which is a combination of insulin icodec and semaglutide, controls blood sugar level in people with type 2 diabetes compared to weekly insulin icodec (COMBINE 1). Available from: https://clinicaltrials.gov/study/NCT05352815. Accessed 12 Feb 2024

44.

ClinicalTrials.gov [Internet], National Library of Medicine, Bethesda, MD, USA. NCT05259033. A research study to see how well the new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar level in people with type 2 diabetes compared to weekly semaglutide (COMBINE 2). 28 Feb 2022. Available from: https://clinicaltrials.gov/study/NCT05259033. Accessed 12 Feb 2024

45.

ClinicalTrials.gov [Internet], National Library of Medicine, Bethesda, MD, USA. NCT05013229. A research study to see how well the new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar level in people with type 2 diabetes compared to insulin glargine taken daily with insulin aspart (COMBINE 3). 19 Aug 2021. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05013229. Accessed 12 Feb 2024

46.

Moen MF, Zhan M, Walker LD, Einhorn LM, Seliger SL, Fink JC (2009) Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 4(6):1121–1127. https://doi.org/10.2215/CJN.00800209CrossRefPubMedPubMedCentral

47.

Abdelhafiz AH, Rodríguez-Mañas L, Morley JE, Sinclair AJ (2015) Hypoglycemia in older people-a less well recognized risk factor for frailty. Aging Dis 6(2):156–167. https://doi.org/10.14336/AD.2014.0330CrossRefPubMedPubMedCentral

48.

Rosenstock J, Cheng A, Ritzel R et al (2018) More similarities than differences testing insulin glargine 300 units/mL versus insulin degludec 100 units/mL in insulin-naive type 2 diabetes: the randomized head-to-head BRIGHT trial. Diabetes Care 41(10):2147–2154. https://doi.org/10.2337/dc18-0559CrossRefPubMed

49.

ClinicalTrials.gov [Internet], National Library of Medicine, Bethesda, MD, USA. NCT04848480. A research study to compare a new weekly insulin, insulin icodec, and an available daily insulin, insulin degludec, both in combination with mealtime insulin in people with type 1 diabetes (ONWARDS 6). 19 April 2021. Available from https://ClinicalTrials.gov/show/NCT04848480. Accessed 12 Feb 2024

50.

Bajaj HS, Ásbjörnsdóttir B, Carstensen L et al (2024) Continuous glucose monitoring-based metrics and hypoglycemia duration in insulin-experienced individuals with long-standing type 2 diabetes switched from a daily basal insulin to once-weekly insulin icodec: post hoc analysis of ONWARDS 2 and ONWARDS 4. Diabetes Care 47(4):729–738. https://doi.org/10.2337/dc23-2136CrossRefPubMedPubMedCentral

51.

Pieber TR, Arfelt KN, Cailleteau R et al (2023) Hypoglycaemia frequency physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial. Diabetologia 66(8):1413–1430. https://doi.org/10.1007/s00125-023-05921-8CrossRefPubMedPubMedCentral

52.

ElSayed NA, Aleppo G, Aroda VR et al (2023) 16. Diabetes care in the hospital: Standards of Care in Diabetes—2023. Diabetes Care 46(Supplement_1):S267–S278. https://doi.org/10.2337/dc23-S016CrossRefPubMed

53.

Peyrot M, Rubin RR, Kruger DF, Travis LB (2010) Correlates of insulin injection omission. Diabetes Care 33(2):240–245. https://doi.org/10.2337/dc09-1348CrossRefPubMedPubMedCentral

Title: Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes
Authors: Roberto Trevisan
Matteo Conti
Stefano Ciardullo
Publication date: 29-04-2024
Publisher: Springer Berlin Heidelberg
Keywords: Insulins
Diabetes
Diabetes Therapy
Type 2 Diabetes
Type 1 Diabetes
Insulins
Hypoglycemia
Published in: Diabetologia
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-024-06158-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Weekly basal insulin/© Jeniffer / stock.adobe.com, Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com